A new pathway to access Wegovy for obesity The Medicare GLP-1 Bridge Program is a nationwide, short-term CMS program designed to cover select weight-management drugs for Medicare Part D beneficiaries Medicare GLP-1 Bridge Program Eligible patients can access all doses of Wegovy pill and pen for only Starting July 1, 2026 1 Medicare GLP-1 Bridge Program eligibility 1 Medication prescribed for weight management, in combination with current and ongoing lifestyle modification consistent with the applicable FDA-approved label Enrolled in a Medicare Part D plan (stand-alone PDP or MA PD), including Special Needs Plans (SNPs), employer/union group waiver plans (EGWPs), Limited Income Newly Eligible Transition (LI NET), and dual-eligible beneficiaries who are enrolled in eligible Part D plan types 18 years of age BMI 35 kg/m 2 or BMI 30 kg/m 2 + 1 or more of the following comorbidities Uncontrolled HTN, HFpEF, CKD Stage 3a, or above or BMI 27 kg/m 2 + 1 or more comorbidities Pre-diabetes, previous stroke/MI, symptomatic PAD Terms apply
Understanding the potential mechanisms behind this symptom can help patients and clinicians address it appropriately
For instance, Novo Nordisks semaglutide-based drugs (Ozempic, Wegovy) face competition from Eli Lillys tirzepatide-based Mounjaro and Zepbound, which have demonstrated superior weight loss efficacy, while Novo Nordisks CagriSema has recently shown promising but not market-leading results, further intensifying industry competition
For people with IBS, this raises an important question: what happens when a medication designed to slow gut motility meets an already sensitive gut
Super Easy GLP-1 High Protein Cookbook for Weight Loss: Protect Muscle, Stop Side Effects, and Lose Weight with Simple, Delicious High-Protein Recipes That Actually Feel Good on GLP-1 [Landers, Mark L.] on Amazon.com
